APOGEE THERAPEUTICS INC (APGE) Forecast, Price Target & Analyst Ratings
NASDAQ:APGE • US03770N1019
72.19 USD
+1.27 (+1.79%)
Last: Mar 6, 2026, 02:21 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for APOGEE THERAPEUTICS INC (APGE).
Forecast Snapshot
Consensus Price Target
$106.37
+ 47.35% Upside
Next Earnings Forecast
Release DateMay 11, 2026
PeriodQ1 / 2026
EPS Estimate-$1.12
Revenue Estimate
ChartMill Buy Consensus
86.36%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$106.37
Upside
+ 47.35%
From current price of $72.19 to mean target of $106.37, Based on 22 analyst forecasts
Low
$83.83
Median
$99.45
High
$143.85
Price Target Revisions
1 Month
0.87%
3 Months
9.43%
Price Target Summary
22 analysts have analysed APGE and the average price target is 106.37 USD. This implies a price increase of 47.35% is expected in the next year compared to the current price of 72.19.
The average price target has been revised upward by 9.43% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.36%
APGE was analyzed by 22 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about APGE.
In the previous month the buy percentage consensus was at a similar level.
APGE was analyzed by 22 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-03 | RBC Capital | Maintains | Sector Perform -> Sector Perform |
| 2026-03-03 | Wedbush | Maintains | Outperform -> Outperform |
| 2026-01-22 | RBC Capital | Downgrade | Outperform -> Sector Perform |
| 2026-01-07 | Wolfe Research | Initiate | Peer Perform |
| 2026-01-06 | BTIG | Maintains | Buy -> Buy |
| 2026-01-05 | BTIG | Maintains | Buy -> Buy |
| 2025-12-17 | Stephens & Co. | Initiate | Overweight |
| 2025-12-10 | Deutsche Bank | Initiate | Buy |
| 2025-11-03 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-03 | Craig-Hallum | Initiate | Buy |
| 2025-10-21 | Mizuho | Initiate | Outperform |
| 2025-10-09 | BTIG | Reiterate | Buy -> Buy |
| 2025-09-25 | RBC Capital | Initiate | Outperform |
| 2025-08-28 | B of A Securities | Maintains | Buy -> Buy |
| 2025-07-02 | Guggenheim | Reiterate | Buy -> Buy |
| 2025-03-13 | Citigroup | Initiate | Buy |
| 2025-02-10 | Guggenheim | Reiterate | Buy -> Buy |
| 2024-12-12 | Guggenheim | Reiterate | Buy -> Buy |
| 2024-12-03 | Guggenheim | Reiterate | Buy -> Buy |
| 2024-12-02 | Wedbush | Maintains | Outperform -> Outperform |
| 2024-11-27 | Guggenheim | Maintains | Buy -> Buy |
| 2024-11-25 | Canaccord Genuity | Initiate | Buy |
| 2024-10-25 | Wedbush | Reiterate | Outperform -> Outperform |
| 2024-05-10 | B of A Securities | Initiate | Buy |
| 2024-03-06 | Jefferies | Maintains | Buy -> Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 11, 2026
PeriodQ1 / 2026
EPS Estimate-$1.12
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-18.18%
Number of Analysts13
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
1.26%
EPS (3 Months)
3.37%
Next Earnings Summary
APGE is expected to report earnings on 5/11/2026. The consensus EPS estimate for the next earnings is -1.12 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A 722.70% | N/A 304.95% | N/A 99.08% | N/A 71.11% | N/A 39.28% | ||||
| EBITDA YoY % growth | N/A | N/A | -216.681M | N/A -32.48% | N/A -23.31% | N/A -11.00% | N/A -29.93% | N/A 34.57% | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -30.727M | -93.003M -202.68% | -216.87M -133.19% | N/A -32.34% | N/A -24.29% | N/A -20.26% | N/A -22.76% | N/A -0.35% | N/A 59.60% | N/A 350.66% | N/A 167.59% | N/A 29.33% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | N/A | -3.29 -18.55% | -4.22 -28.38% | N/A -19.60% | N/A -19.78% | N/A 6.46% | N/A 13.12% | N/A 51.21% | N/A 266.10% | N/A 176.77% | N/A 58.41% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -1.12 -18.18% | -1.19 -4.93% | -1.21 -8.86% | -1.21 -17.33% | -0.95 15.78% | -0.98 17.59% | -1.03 15.08% | -1.12 7.67% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | ||||
| EBITDA Q2Q % growth | -80.387M -27.82% | -87.539M -20.65% | -88.753M -26.31% | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -80.213M -27.13% | -85.185M -16.43% | -87.268M -22.43% | -91.188M -18.14% | N/A | N/A | N/A | N/A |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-10.25%
EPS Next 5 Year
7.45%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-22.57%
EBIT Next 5 Year
-9.37%
APOGEE THERAPEUTICS INC / APGE Forecast FAQ
What is the average price target for APOGEE THERAPEUTICS INC (APGE) stock?
22 analysts have analysed APGE and the average price target is 106.37 USD. This implies a price increase of 47.35% is expected in the next year compared to the current price of 72.19.
Can you provide the upcoming earnings date for APOGEE THERAPEUTICS INC?
APOGEE THERAPEUTICS INC (APGE) will report earnings on 2026-05-11.
Can you provide the consensus estimates for APOGEE THERAPEUTICS INC next earnings?
The consensus EPS estimate for the next earnings of APOGEE THERAPEUTICS INC (APGE) is -1.12 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for APOGEE THERAPEUTICS INC (APGE) stock?
The consensus rating for APOGEE THERAPEUTICS INC (APGE) is 86.3636 / 100 . This indicates that analysts generally have a positive outlook on the stock.